Harmony Biosciences reported Q3 WACIX net revenue of $269 million and reiterated 2026 guidance of $1 to $1.04 billion. BP-205 showed an approximately 29-hour effective half-life, and Peter Anastasiou will become CEO on January 1, 2027.
HRMY · Harmony Biosciences Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Harmony’s net product revenue increased $29.5 million, or 12.3%, for the three months ended September 30, 2026. Pitolisant GR received full FDA review with a target PDUFA date of April 1, 2027.
Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.
Harmony Biosciences Holdings, Inc. said Jeffrey M. Dayno will retire as CEO effective December 31, 2026, receive $770,000, and be succeeded by Peter Anastasiou effective January 1, 2027. Anastasiou’s salary will be $725,000, with equity awards of $1,750,000 and $750,000.
Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou CEO and director effective January 1, 2027; Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026. Full-year 2026 WAKIX net revenue guidance remains $1.0 billion to $1.04 billion.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q1 FY26 earnings call · May 7, 2026TL;DR. Q1 2026 WAKIX net revenue rose 17% to $215.4 million, and management reiterated full-year 2026 net revenue guidance of $1.00 to $1.04 billion. Net income fell to $32.5 million ($0.55 per diluted share) because of $32 million in upfront amorphous-license charges, and the BP-205 Phase 1 PK data readout is expected in mid-2026.
- + Q1 WAKIX net product revenue grew 17% year over year to $215.4 million.
- + Full-year 2026 WAKIX net revenue guidance of $1.00 to $1.04 billion was reiterated.
- + BP-205 Phase 1 single-ascending-dose PK data readout is on track for mid-2026.
- − Net income fell to $32.5 million ($0.55 per diluted share) from $45.6 million ($0.78) a year earlier.
- − Cost of product sold rose to 20.7% of net product revenue from 17.3%, driven by new Novitium license royalties.
- − Higher-than-usual market access headwinds, including plan switching and premium increases, delayed some patient starts.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average patients | 8,950 | Q2 2026 | — |
| Cash, cash equivalents and investments | $962.5M | as of June 30, 2026 | — |
| Cost of product sold as a percentage of net product revenue | 24.2% | second quarter of 2026 | — |
| Net patient adds | 450 | 2Q26 | — |
| number of units shipped | 26.5% | the three months ended June 30, 2026 filing | — |
| WAKIX net product revenue growth | 30% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HRMY
this stock
Harmony Biosciences Holdings, Inc.
|
$1.94B | -11.8% | +21.5% | 10.9 | 11.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 20
Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HRMY | -1.6% | -14.7% | +4.8% | -14.8% | -11.8% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +0.7% | -9.9% | +7.8% | -11.8% | -19.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.